Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.

PubWeight™: 1.58‹?› | Rank: Top 4%

🔗 View Article (PMC 1180332)

Published in Am J Hum Genet on February 27, 2003

Authors

Mieke Schutte1, Sheila Seal, Rita Barfoot, Hanne Meijers-Heijboer, Marijke Wasielewski, D Gareth Evans, Diana Eccles, Carel Meijers, Frans Lohman, Jan Klijn, Ans van den Ouweland, P Andrew Futreal, Katherine L Nathanson, Barbara L Weber, Douglas F Easton, Michael R Stratton, Nazneen Rahman, Breast Cancer Linkage Consortium

Author Affiliations

1: Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.

Articles citing this

Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24

CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet (2004) 3.97

CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet (2004) 3.03

CHEK2 variants associate with hereditary prostate cancer. Br J Cancer (2003) 1.54

Pathology of hereditary breast cancer. Cell Oncol (Dordr) (2011) 1.28

A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet (2006) 1.24

Linkage disequilibrium mapping of CHEK2: common variation and breast cancer risk. PLoS Med (2006) 1.23

CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet (2006) 1.10

Frequency of CHEK2 mutations in a population based, case-control study of breast cancer in young women. Breast Cancer Res (2004) 1.00

CHEK2 contribution to hereditary breast cancer in non-BRCA families. Breast Cancer Res (2011) 0.97

Gene-gene interactions in breast cancer susceptibility. Hum Mol Genet (2011) 0.97

Identification of women with an increased risk of developing radiation-induced breast cancer. Breast Cancer Res (2007) 0.88

Fusion of the tumor-suppressor gene CHEK2 and the gene for the regulatory subunit B of protein phosphatase 2 PPP2R2A in childhood teratoma. Neoplasia (2006) 0.88

Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women. BMC Cancer (2008) 0.86

Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan. BMC Cancer (2013) 0.83

CHEK2*1100delC does not contribute to risk to breast cancer among Malay, Chinese and Indians in Malaysia. Fam Cancer (2009) 0.82

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. J Clin Oncol (2016) 0.81

Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. BMC Med Genet (2014) 0.80

The c.470 T > C CHEK2 missense variant increases the risk of differentiated thyroid carcinoma in the Great Poland population. Hered Cancer Clin Pract (2015) 0.79

Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol (2016) 0.77

Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genet Med (2016) 0.76

Molecular tumor profiling: translating genomic insights into clinical advances. Genome Biol (2004) 0.76

Inherited and acquired alterations in development of breast cancer. Appl Clin Genet (2011) 0.75

Low prevalence of CHEK2 gene mutations in multiethnic cohorts of breast cancer patients in Malaysia. PLoS One (2015) 0.75

Articles cited by this

The DNA damage response: putting checkpoints in perspective. Nature (2000) 19.07

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71

Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science (1998) 8.74

The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature (2001) 6.73

Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev (2000) 5.90

Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A (2000) 5.64

Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci U S A (1993) 5.47

Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (1999) 5.09

BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet (1997) 3.68

hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature (2000) 3.65

The molecular basis of FHA domain:phosphopeptide binding specificity and implications for phospho-dependent signaling mechanisms. Mol Cell (2000) 3.64

Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1. Nature (1998) 3.36

A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet (2002) 3.00

CHK2 kinase--a busy messenger. Nat Rev Mol Cell Biol (2001) 2.68

Structural and functional versatility of the FHA domain in DNA-damage signaling by the tumor suppressor kinase Chk2. Mol Cell (2002) 1.99

Chk2 activation and phosphorylation-dependent oligomerization. Mol Cell Biol (2002) 1.88

p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res (2001) 1.74

Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet (2001) 1.70

Characterization of tumor-associated Chk2 mutations. J Biol Chem (2000) 1.63

Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res (2001) 1.51

Mutation analysis of the CHK2 gene in families with hereditary breast cancer. Br J Cancer (2001) 1.39

Concomitant inactivation of p53 and Chk2 in breast cancer. Oncogene (2002) 1.19

A robust method for detecting CHK2/RAD53 mutations in genomic DNA. Hum Mutat (2002) 1.13

The North Cumbria Community Genetics Project. J Med Genet (1998) 1.08

Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. Leuk Res (2001) 1.05

Mutation analysis of the CHK2 gene in breast carcinoma and other cancers. Breast Cancer Res (2002) 0.92

Analysis of CHK2 in vulval neoplasia. Br J Cancer (2002) 0.84

Articles by these authors

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat Genet (2008) 43.63

Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41

A census of human cancer genes. Nat Rev Cancer (2004) 36.20

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78

Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res (2010) 25.55

A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27

The cancer genome. Nature (2009) 23.13

Signatures of mutational processes in human cancer. Nature (2013) 21.63

International network of cancer genome projects. Nature (2010) 20.35

A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39

Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell (2011) 16.72

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12

Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91

Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature (2010) 14.50

Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet (2004) 14.31

The tuberous sclerosis complex. N Engl J Med (2006) 13.53

Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature (2009) 13.45

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature (2011) 13.30

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature (2011) 13.18

Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell (2010) 12.50

The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature (2010) 12.43

Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27

The landscape of cancer genes and mutational processes in breast cancer. Nature (2012) 11.24

Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22

The life history of 21 breast cancers. Cell (2012) 10.59

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21

Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75

Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71

Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med (2008) 9.64

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res (2009) 9.59

PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93